ATE196150T1 - Regulation der aktivität von lymphozyten durch hla-peptide - Google Patents

Regulation der aktivität von lymphozyten durch hla-peptide

Info

Publication number
ATE196150T1
ATE196150T1 AT93918763T AT93918763T ATE196150T1 AT E196150 T1 ATE196150 T1 AT E196150T1 AT 93918763 T AT93918763 T AT 93918763T AT 93918763 T AT93918763 T AT 93918763T AT E196150 T1 ATE196150 T1 AT E196150T1
Authority
AT
Austria
Prior art keywords
peptides
regulation
lymphocyte activity
domains
hla peptides
Prior art date
Application number
AT93918763T
Other languages
English (en)
Inventor
Carol A Clayberger
Alan M Krensky
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE196150T1 publication Critical patent/ATE196150T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT93918763T 1992-03-02 1993-02-25 Regulation der aktivität von lymphozyten durch hla-peptide ATE196150T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/844,716 US5888512A (en) 1987-01-30 1992-03-02 Lymphocyte activity regulation by HLA peptides
PCT/US1993/001758 WO1993017699A1 (en) 1992-03-02 1993-02-25 Lymphocyte activity regulation by hla peptides

Publications (1)

Publication Number Publication Date
ATE196150T1 true ATE196150T1 (de) 2000-09-15

Family

ID=25293452

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918763T ATE196150T1 (de) 1992-03-02 1993-02-25 Regulation der aktivität von lymphozyten durch hla-peptide

Country Status (12)

Country Link
US (1) US5888512A (de)
EP (1) EP0631502B1 (de)
JP (1) JP2846470B2 (de)
AT (1) ATE196150T1 (de)
AU (1) AU678381B2 (de)
CA (1) CA2131299A1 (de)
DE (1) DE69329379T2 (de)
DK (1) DK0631502T3 (de)
ES (1) ES2150949T3 (de)
GR (1) GR3034964T3 (de)
PT (1) PT631502E (de)
WO (1) WO1993017699A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723128A (en) * 1987-01-30 1998-03-03 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
US7011834B1 (en) 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US5639458A (en) * 1987-03-20 1997-06-17 Regents Of The University Of California Class I MHC modulation of surface receptor activity
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
AU1093995A (en) * 1993-11-10 1995-05-29 Board Of Trustees Of The Leland Stanford Junior University Surface membrane proteins and their effect on immune response
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
DE69617396T2 (de) * 1995-01-16 2002-09-05 Northern Sydney Area Health Service, St. Leonards T-Zellen beeinflussende Peptide
US6162434A (en) 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
WO1997024140A1 (en) * 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
US6436903B1 (en) 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
EP0950065B1 (de) * 1996-09-18 2003-02-19 Gerhild Wildner Peptide als diagnostikum und therapeutikum für autoimmunerkrankungen
WO1998022141A2 (en) * 1996-11-19 1998-05-28 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
BR9808529B1 (pt) 1997-04-11 2010-10-05 oligopeptìdeo.
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
NZ521898A (en) 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
US7094413B2 (en) 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20090023895A1 (en) 2006-02-07 2009-01-22 Nec Corporation Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
GB0609121D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
EP2434014B1 (de) 2006-10-12 2014-12-10 Nec Corporation HLA bindendes Peptid, dessen Vorstufe, dafür codierendes DNA-Fragment und rekombinanter Vektor
US20110038881A1 (en) * 2007-05-09 2011-02-17 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
CA2694824A1 (en) * 2007-08-09 2009-02-12 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US5202424A (en) * 1984-03-19 1993-04-13 The Rockefeller University Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
WO1988005784A1 (en) * 1987-01-30 1988-08-11 The Board Of Trustees Of The Leland Stanford Junio Lymphocyte inhibition by hla peptides
JPH03504493A (ja) * 1988-02-12 1991-10-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞性免疫の発生及び操作のための合成ペプチドの使用
EP0459978B1 (de) * 1989-03-03 1997-07-16 The Regents Of The University Of California Klasse i-mhc-modulation von oberflächenrezeptoraktivität
US5073540A (en) * 1989-05-15 1991-12-17 Receptron Composite binding site drugs
CA2081582A1 (en) * 1991-11-05 1993-05-06 Teodorica Bugawan Methods and reagents for hla class i dna typing

Also Published As

Publication number Publication date
AU4807893A (en) 1993-10-05
US5888512A (en) 1999-03-30
DE69329379T2 (de) 2001-03-29
JPH08504168A (ja) 1996-05-07
GR3034964T3 (en) 2001-02-28
ES2150949T3 (es) 2000-12-16
DK0631502T3 (da) 2001-01-02
WO1993017699A1 (en) 1993-09-16
DE69329379D1 (de) 2000-10-12
CA2131299A1 (en) 1993-09-16
PT631502E (pt) 2001-03-30
EP0631502A1 (de) 1995-01-04
EP0631502A4 (de) 1996-07-24
AU678381B2 (en) 1997-05-29
JP2846470B2 (ja) 1999-01-13
EP0631502B1 (de) 2000-09-06

Similar Documents

Publication Publication Date Title
DE69329379D1 (de) Regulation der aktivität von lymphozyten durch hla-peptide
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
ATE231884T1 (de) Die regulation der aktivität zytotoxischer t- zelllymphozyten mit peptiden der mhc-klasse i
Storkus et al. Peptide-induced modulation of target cell sensitivity to natural killing
DE69329344D1 (de) Spezifische modulationen des immunsystems
ATE126237T1 (de) Lymphocyteninhibierung durch hla-peptide.
BR9406652A (pt) Composição
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
NO943967D0 (no) Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider
DK289285D0 (da) Thymopentin analoge
DK0633763T3 (da) Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
FI953093A0 (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
DE69637078D1 (de) Polypeptid-fragmente die fähig sind mit dem antigen i/ii von streptococcus mutans zu konkurrieren
ATE139259T1 (de) Selbstantigen der primären lebercirrhose
NO970803L (no) Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer
DE69929683D1 (de) Antisense modulierung von lfa-3
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
DK0597043T3 (da) Porcine adipocytantigener og deres anvendelse til immunologisk bekæmpelse af fedt
Schauenstein et al. STUDIES ON THE COMPLEMENT RECEPTOR OF CHICKEN SPLEEN CELLS
ZA95669B (en) Analogs of thymosin alpha1
SU1331063A1 (ru) ШТАММ TRICHODERMA HARZIANUM RIFAI - ПРОДУЦЕНТ L-ФЕНИЛАЛАНИН-α-ОКСИДАЗЫ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee